237 related articles for article (PubMed ID: 10821971)
21. Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease.
Hegde NR; Gore MM
Hum Vaccin Immunother; 2017 Jun; 13(6):1-18. PubMed ID: 28301270
[TBL] [Abstract][Full Text] [Related]
22. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.
Monath TP; Soike K; Levenbook I; Zhang ZX; Arroyo J; Delagrave S; Myers G; Barrett AD; Shope RE; Ratterree M; Chambers TJ; Guirakhoo F
Vaccine; 1999 Apr; 17(15-16):1869-82. PubMed ID: 10217584
[TBL] [Abstract][Full Text] [Related]
23. Japanese encephalitis vaccine-facilitated dengue virus infection-enhancement antibody in adults.
Saito Y; Moi ML; Takeshita N; Lim CK; Shiba H; Hosono K; Saijo M; Kurane I; Takasaki T
BMC Infect Dis; 2016 Oct; 16(1):578. PubMed ID: 27756212
[TBL] [Abstract][Full Text] [Related]
24. Japanese encephalitis vaccines: current vaccines and future prospects.
Monath TP
Curr Top Microbiol Immunol; 2002; 267():105-38. PubMed ID: 12082985
[TBL] [Abstract][Full Text] [Related]
25. Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines.
Markoff L
Vaccine; 2000 May; 18 Suppl 2():26-32. PubMed ID: 10821970
[TBL] [Abstract][Full Text] [Related]
26. Homologous and heterologous neutralization antibody responses after immunization with Japanese encephalitis vaccine among Taiwan children.
Ku CC; King CC; Lin CY; Hsu HC; Chen LY; Yueh YY; Chang GJ
J Med Virol; 1994 Oct; 44(2):122-31. PubMed ID: 7852952
[TBL] [Abstract][Full Text] [Related]
27. Potency testing of inactivated tissue culture vaccine against Japanese encephalitis using antigen capture ELISA.
Joshi AM; Walimbe AM; Banerjee K
Acta Virol; 1997 Jun; 41(3):157-9. PubMed ID: 9385404
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis.
Guirakhoo F; Zhang ZX; Chambers TJ; Delagrave S; Arroyo J; Barrett AD; Monath TP
Virology; 1999 May; 257(2):363-72. PubMed ID: 10329547
[TBL] [Abstract][Full Text] [Related]
29. A field study on Nakayama and Beijing strains of Japanese encephalitis vaccines.
Nimmannitya S; Hutamai S; Kalayanarooj S; Rojanasuphot S
Southeast Asian J Trop Med Public Health; 1995 Dec; 26(4):689-93. PubMed ID: 9139377
[TBL] [Abstract][Full Text] [Related]
30. Safety and immunogenicity of a freeze-dried, Vero cell culture-derived, inactivated Japanese encephalitis vaccine (KD-287, ENCEVAC®) versus a mouse brain-derived inactivated Japanese encephalitis vaccine in children: a phase III, multicenter, double-blinded, randomized trial.
Yun KW; Lee HJ; Kang JH; Eun BW; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
BMC Infect Dis; 2015 Jan; 15():7. PubMed ID: 25567119
[TBL] [Abstract][Full Text] [Related]
31. A purified inactivated Japanese encephalitis virus vaccine made in Vero cells.
Srivastava AK; Putnak JR; Lee SH; Hong SP; Moon SB; Barvir DA; Zhao B; Olson RA; Kim SO; Yoo WD; Towle AC; Vaughn DW; Innis BL; Eckels KH
Vaccine; 2001 Aug; 19(31):4557-65. PubMed ID: 11483284
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children.
Janewongwirot P; Puthanakit T; Anugulruengkitt S; Jantarabenjakul W; Phasomsap C; Chumket S; Yoksan S; Pancharoen C
Vaccine; 2016 Oct; 34(44):5279-5283. PubMed ID: 27628323
[TBL] [Abstract][Full Text] [Related]
33. Trial of inactivated Japanese encephalitis vaccine in children with underlying diseases.
Yamada A; Imanishi J; Juang RF; Fukunaga T; Okuno Y; Tadano M; Fukai K; Baba K; Yabuuchi H
Vaccine; 1986 Mar; 4(1):32-4. PubMed ID: 3008460
[TBL] [Abstract][Full Text] [Related]
34. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children From a Japanese Encephalitis Virus-endemic Region.
Dubischar KL; Kadlecek V; Sablan JB; Borja-Tabora CF; Gatchalian S; Eder-Lingelbach S; Kiermayr S; Spruth M; Westritschnig K
Pediatr Infect Dis J; 2017 Sep; 36(9):898-904. PubMed ID: 28430748
[TBL] [Abstract][Full Text] [Related]
36. Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in children.
Chokephaibulkit K; Sirivichayakul C; Thisyakorn U; Pancharoen C; Boaz M; Bouckenooghe A; Feroldi E
Vaccine; 2016 Nov; 34(46):5664-5669. PubMed ID: 27686833
[TBL] [Abstract][Full Text] [Related]
37. Japanese encephalitis virus-specific proliferative responses of human peripheral blood T lymphocytes.
Konishi E; Kurane I; Mason PW; Innis BL; Ennis FA
Am J Trop Med Hyg; 1995 Sep; 53(3):278-83. PubMed ID: 7573713
[TBL] [Abstract][Full Text] [Related]
38. Japanese encephalitis. Inactivated Japanese encephalitis virus vaccine.
Wkly Epidemiol Rec; 1994 Apr; 69(16):113-8. PubMed ID: 8003406
[No Abstract] [Full Text] [Related]
39. IMOJEV(®): a Yellow fever virus-based novel Japanese encephalitis vaccine.
Appaiahgari MB; Vrati S
Expert Rev Vaccines; 2010 Dec; 9(12):1371-84. PubMed ID: 21105774
[TBL] [Abstract][Full Text] [Related]
40. Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis.
Paulke-Korinek M; Kollaritsch H; Kundi M; Zwazl I; Seidl-Friedrich C; Jelinek T
Vaccine; 2015 Jul; 33(30):3600-4. PubMed ID: 26036947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
